Sweet syndrome in a patient receiving encorafenib and binimetinib therapy for malignant melanoma

JAAD Case Rep. 2024 Feb 4:45:91-93. doi: 10.1016/j.jdcr.2024.01.025. eCollection 2024 Mar.

Authors

Myiah Quach¹, John P Antonelli¹, Charlotte LaSenna^{1

2}, Mackenzie Asel^{1

2}, Jennifer Pleva³, Vincent T Ma^{1

2

4}

Affiliations

¹ University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
² Department of Dermatology, University of Wisconsin-Madison, Madison, Wisconsin.
³ UW Health, Madison, Wisconsin.
⁴ Division of Hematology, Medical Oncology and Palliative Care, Department of Medicine, University of Wisconsin-Madison, Madison, Wisconsin.

No abstract available

Keywords: Sweet syndrome; binimetinib; encorafenib; immune-related adverse events; melanoma.

Publication types

Case Reports